東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Integrated Glycomics and Proteomics ...

Raghunathan, Rekha.

Linked to FindBook

Google Book

Amazon

博客來

Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer./
Author:	Raghunathan, Rekha.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	213 p.
Notes:	Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
Contained By:	Dissertations Abstracts International81-04B.
Subject:	Biochemistry. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22616897
ISBN:	9781687954565

Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer.
Raghunathan, Rekha.

Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 213 p.

Source: Dissertations Abstracts International, Volume: 81-04, Section: B.

Thesis (Ph.D.)--Boston University, 2019.

This item must not be sold to any third party vendors.

Parkinson's disease (PD) is a neurological disorder characterized by the lack of functional dopaminergic neurons in the nigrostriatal pathway in the brain. Current therapeutic strategies for the disease provide temporary symptomatic relief. Gene therapy has the potential to improve dopamine production in Parkinson's disease patients. Adeno-associated viruses (AAV) are the vectors of choice in gene therapy for PD, due to their well-characterized safety and efficacy profiles, with all primary receptors being glycans. The problem with using AAV in PD gene therapy is that the aged brain is resistant to transduction of the virus, while PD primarily occurs with age. Thus, in Aim 1 we characterize the age-related changes in glycan receptors in the nigrostriatal pathway as a baseline to address current challenges in gene delivery in Parkinson's disease. To make these measurements from specific regions of tissue, we develop a platform that incorporates on-slide digestion followed by LC-MS/MS for integrated glycomics and proteomics. Further, we apply this to understand aging- and PD-related changes in the human pre-frontal cortex in Aims 2 and 3, to understand normal and pathological aging processes as well as integrate this information with transcriptomics data, to assess risk factors that may contribute to Parkinson's disease. Finally, we also apply the method to investigate cancer premalignancy and heterogeneity. Our on-slide method, used herein to study aging, Parkinson's disease and cancer, can be applied to any precious biopsy specimens to enable glycomic and proteomic profiling in diverse diseases, and thus may have a broad impact on biomedical research.

ISBN: 9781687954565Subjects--Topical Terms:

518028
Biochemistry.
Subjects--Index Terms:

aging

Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer.
LDR:02833nmm a2200385 4500 001 2272748
005 20201105110213.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781687954565
035 $a (MiAaPQ)AAI22616897
035 $a AAI22616897
040 $a MiAaPQ $c MiAaPQ
100 1 $a Raghunathan, Rekha. $3 3550174
245 1 0 $a Integrated Glycomics and Proteomics in Aging, Parkinson's Disease and Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 213 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
500 $a Advisor: Zaia, Joseph.
502 $a Thesis (Ph.D.)--Boston University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Parkinson's disease (PD) is a neurological disorder characterized by the lack of functional dopaminergic neurons in the nigrostriatal pathway in the brain. Current therapeutic strategies for the disease provide temporary symptomatic relief. Gene therapy has the potential to improve dopamine production in Parkinson's disease patients. Adeno-associated viruses (AAV) are the vectors of choice in gene therapy for PD, due to their well-characterized safety and efficacy profiles, with all primary receptors being glycans. The problem with using AAV in PD gene therapy is that the aged brain is resistant to transduction of the virus, while PD primarily occurs with age. Thus, in Aim 1 we characterize the age-related changes in glycan receptors in the nigrostriatal pathway as a baseline to address current challenges in gene delivery in Parkinson's disease. To make these measurements from specific regions of tissue, we develop a platform that incorporates on-slide digestion followed by LC-MS/MS for integrated glycomics and proteomics. Further, we apply this to understand aging- and PD-related changes in the human pre-frontal cortex in Aims 2 and 3, to understand normal and pathological aging processes as well as integrate this information with transcriptomics data, to assess risk factors that may contribute to Parkinson's disease. Finally, we also apply the method to investigate cancer premalignancy and heterogeneity. Our on-slide method, used herein to study aging, Parkinson's disease and cancer, can be applied to any precious biopsy specimens to enable glycomic and proteomic profiling in diverse diseases, and thus may have a broad impact on biomedical research.
590 $a School code: 0017.
650 4 $a Biochemistry. $3 518028
650 4 $a Analytical chemistry. $3 3168300
650 4 $a Neurosciences. $3 588700
653 $a aging
653 $a cancer
653 $a glycomics
653 $a multi-omics
653 $a Parkinson's disease
653 $a proteomics
690 $a 0487
690 $a 0486
690 $a 0317
710 2 $a Boston University. $b Molecular and Translational Medicine GMS. $3 3285971
773 0 $t Dissertations Abstracts International $g 81-04B.
790 $a 0017
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22616897